Abstract
This study aimed to evaluate the outcome of germline clinical genetic testing in uveal melanoma (UM) patients who met the National Comprehensive Cancer Network (NCCN) guidelines for genetic testing. A retrospective chart review was conducted on UM patients seen in The Ohio State University Cancer Genetics Clinic between 5/1/2021-9/19/2025. Seventy individuals underwent clinical genetic testing, primarily via large multi-gene panels. Ten UM patients, including two related individuals, had pathogenic or likely pathogenic (P/LP) variants in known cancer genes ( BAP1, BRCA1, BRCA2, MBD4, MUTYH, POT1, XRCC2) . Among unrelated individuals, the positive rate was12.9% (8/70). Excluding carrier genes, the rate was10% (7/70) Eight patients would have been missed if only tested for BAP1 per ASCO 2024 recommendations. There was no association between tumor size, stage and germline P/LP variants. In summary, NCCN guidelines are useful in the prioritization of UM patients for genetic testing. Additionally, large panel testing, rather than BAP1 single gene testing, is recommended.